Eptifibatide Injection — Competitive Intelligence Brief

Eptifibatide Injection (Eptifibatide Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glycoprotein IIb/IIIa inhibitor. Area: Cardiovascular.

phase 3 Glycoprotein IIb/IIIa inhibitor Glycoprotein IIb/IIIa receptor Cardiovascular Small molecule

Target snapshot

Eptifibatide Injection (Eptifibatide Injection) — Ministry of Science and Technology of the People´s Republic of China. Eptifibatide is a glycoprotein IIb/IIIa inhibitor that blocks platelet aggregation by preventing fibrinogen binding to platelet receptors.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Eptifibatide Injection TARGET	Eptifibatide Injection	Ministry of Science and Technology of the People´s Republic of China	phase 3	Glycoprotein IIb/IIIa inhibitor	Glycoprotein IIb/IIIa receptor
Glycoprotein IIb/IIIa inhibitors	Glycoprotein IIb/IIIa inhibitors	University of Luebeck	marketed	Glycoprotein IIb/IIIa inhibitor	Glycoprotein IIb/IIIa receptor
Abciximab + UFH	Abciximab + UFH	Deutsches Herzzentrum Muenchen	marketed	Glycoprotein IIb/IIIa inhibitor (in combination with anticoagulant)	Platelet glycoprotein IIb/IIIa receptor
Bivalirudin with and without eptifibatide	Bivalirudin with and without eptifibatide	LifeBridge Health	marketed	Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide)	Thrombin (Factor IIa) and Glycoprotein IIb/IIIa receptor
Tirofiban+Oral Dual Antiplatelet Therapy	Tirofiban+Oral Dual Antiplatelet Therapy	Second Affiliated Hospital of Soochow University	marketed	Glycoprotein IIb/IIIa inhibitor + Dual antiplatelet therapy	Glycoprotein IIb/IIIa receptor
A-Phase: tirofiban; Z-Phase simvastatin	A-Phase: tirofiban; Z-Phase simvastatin	Organon and Co	phase 3	Antiplatelet agent + HMG-CoA reductase inhibitor (combination therapy)	Glycoprotein IIb/IIIa receptor (tirofiban); HMG-CoA reductase (simvastatin)
Intravenous Tirofiban	Intravenous Tirofiban	Beijing Tiantan Hospital	phase 3	Glycoprotein IIb/IIIa inhibitor	Glycoprotein IIb/IIIa receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glycoprotein IIb/IIIa inhibitor class)

1. Beijing Tiantan Hospital · 1 drug in this class
2. Centocor, Inc. · 1 drug in this class
3. General Hospital of Shenyang Military Region · 1 drug in this class
4. Ministry of Science and Technology of the People´s Republic of China · 1 drug in this class
5. Organon and Co · 1 drug in this class
6. Ottawa Heart Institute Research Corporation · 1 drug in this class
7. University of Leipzig · 1 drug in this class
8. University of Luebeck · 1 drug in this class
9. Università degli Studi di Ferrara · 1 drug in this class